AT Bancorp bought a new position in bluebird bio Inc (NASDAQ:BLUE) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 2,609 shares of the biotechnology company’s stock, valued at approximately $409,000.

A number of other large investors also recently made changes to their positions in BLUE. Wealthcare Advisory Partners LLC purchased a new stake in bluebird bio during the first quarter valued at about $171,000. XR Securities LLC bought a new position in shares of bluebird bio during the second quarter valued at about $212,000. Laurel Wealth Advisors Inc. bought a new position in shares of bluebird bio during the first quarter valued at about $215,000. Opus Point Partners Management LLC bought a new position in bluebird bio in the first quarter worth about $226,000. Finally, Cambridge Investment Research Advisors Inc. bought a new position in bluebird bio in the first quarter worth about $233,000. Institutional investors own 97.11% of the company’s stock.

In related news, COO Susanna Gatti High sold 3,500 shares of the firm’s stock in a transaction that occurred on Monday, June 4th. The shares were sold at an average price of $199.11, for a total value of $696,885.00. Following the sale, the chief operating officer now owns 21,000 shares in the company, valued at $4,181,310. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jeffrey T. Walsh sold 1,500 shares of the firm’s stock in a transaction that occurred on Friday, August 10th. The stock was sold at an average price of $156.93, for a total transaction of $235,395.00. Following the completion of the sale, the insider now owns 36,995 shares in the company, valued at approximately $5,805,625.35. The disclosure for this sale can be found here. In the last quarter, insiders have sold 70,327 shares of company stock worth $11,892,567. Corporate insiders own 3.00% of the company’s stock.

NASDAQ:BLUE opened at $158.00 on Friday. bluebird bio Inc has a 52 week low of $90.75 and a 52 week high of $236.17. The company has a market cap of $8.57 billion, a PE ratio of -20.49 and a beta of 2.02.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($2.91) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.30) by ($0.61). bluebird bio had a negative net margin of 1,281.01% and a negative return on equity of 31.57%. The firm had revenue of $7.80 million for the quarter, compared to analysts’ expectations of $10.68 million. During the same quarter in the previous year, the company earned ($1.73) EPS. The company’s quarterly revenue was down 53.3% compared to the same quarter last year. sell-side analysts forecast that bluebird bio Inc will post -10.73 EPS for the current year.

BLUE has been the subject of a number of research reports. SunTrust Banks reissued a “buy” rating and issued a $223.00 price target on shares of bluebird bio in a research note on Friday, August 3rd. ValuEngine raised shares of bluebird bio from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. BidaskClub downgraded shares of bluebird bio from a “hold” rating to a “sell” rating in a research note on Wednesday, June 27th. Piper Jaffray Companies initiated coverage on shares of bluebird bio in a research note on Wednesday, May 30th. They issued a “buy” rating and a $240.00 price target for the company. Finally, Cantor Fitzgerald raised shares of bluebird bio from an “underweight” rating to an “overweight” rating in a research note on Monday, June 4th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. bluebird bio has an average rating of “Buy” and an average target price of $212.05.

bluebird bio Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Read More: Understanding Analyst Recommendations

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.